4.8 Article

Early Loss of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Activates Key Immune Pathways That Facilitate Progression of Ovarian Cancer

Journal

CANCER RESEARCH
Volume 79, Issue 4, Pages 760-772

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-18-2297

Keywords

-

Categories

Funding

  1. National Cancer Institute [P50-CA083636]
  2. NIH [U01 CA152990]
  3. Honorable Tina Brozman Tina's Wish Foundation
  4. Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
  5. European Research Council [293438]
  6. Basser Center for BRCA
  7. Department of Obstetrics and Gynecology at the University of Pennsylvania Perelman School of Medicine
  8. American Cancer Society [SIOP-06-258-01-COUN]
  9. Foundation for Women's Wellness
  10. Claneil Foundation
  11. Run and Walk for Family and Friends with Cancer Foundation
  12. Ann and Sol Schreiber Mentored Investigator Award from the Ovarian Cancer Research Alliance
  13. European Research Council (ERC) [293438] Funding Source: European Research Council (ERC)

Ask authors/readers for more resources

Recent insights supporting the fallopian tube epithelium (FTE) and serous tubal intraepithelial carcinomas (STIC) as the tissue of origin and the precursor lesion, respectively, for the majority of high-grade serous ovarian carcinomas (HGSOC) provide the necessary context to study the mechanisms that drive the development and progression of HGSOC. Here, we investigate the role of the E3 ubiquitin ligase RNF20 and histone H2B monoubiquitylation (H2Bub1) in serous tumorigenesis and report that heterozygous loss of RNF20 defines the majority of HGSOC tumors. At the protein level, H2Bub1 was lost or downregulated in a large proportion of STIC and invasive HGSOC tumors, implicating RNF20/H2Bub1 loss as an early event in the development of serous ovarian carcinoma. Knockdown of RNF20, with concomitant loss of H2Bub1, was sufficient to enhance cell migration and clonogenic growth of FTE cells. To investigate the mechanisms underlying these effects, we performed ATAC-seq and RNA-seq in RNF20 knockdown FTE cell lines. Loss of RNF20 and H2Bub1 was associated with a more open chromatin conformation, leading to upregulation of immune signaling pathways, including IL6. IL6 was one of the key cytokines significantly upregulated in RNF20- and H2Bub1-depleted FTE cells and imparted upon these cells an enhanced migratory phenotype. These studies provide mechanistic insight into the observed oncogenic phenotypes triggered by the early loss of H2Bub1. Significance: Loss of RNF20 and H2Bub1 contributes to transformation of the fallopian tube epithelium and plays a role in the initiation and progression of high-grade serous ovarian cancer. Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/79/4/760/F1.large.jpg.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Biochemistry & Molecular Biology

Cell Fitness: More Than Push-Ups

Adam James Ferrari, Ronny Drapkin, Rajan Gogna

Summary: Cell competition allows tumor cells to outcompete adjacent less fit cells. Recent studies have identified molecular fitness fingerprint, oncogenic pathways, and cell junction stability as key factors in determining the outcome of cell competition. Understanding these features may open up possibilities for new diagnostic and therapeutic approaches in cancer treatment.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Article Oncology

Deubiquitinase UCHL1 Maintains Protein Homeostasis through the PSMA7-APEH-Proteasome Axis in High-grade Serous Ovarian Carcinoma

Apoorva Tangri, Kinzie Lighty, Jagadish Loganathan, Fahmi Mesmar, Ram Podicheti, Chi Zhang, Marcin Iwanicki, Ronny Drapkin, Harikrishna Nakshatri, Sumegha Mitra

Summary: The study found that the overexpression of neuronal deubiquitinating enzyme UCHL1 in HGSOC promotes tumor growth by maintaining protein homeostasis. Inhibition of UCHL1 can reduce tumor cell proliferation and invasion, as well as decrease the metastatic growth of ovarian cancer xenografts. This indicates that UCHL1 plays a crucial role in HGSOC progression through the regulation of protein homeostasis.

MOLECULAR CANCER RESEARCH (2021)

Article Biology

Co-regulation and function of FOXM1/RHNO1 bidirectional genes in cancer

Carter J. Barger, Linda Chee, Mustafa Albahrani, Catalina Munoz-Trujillo, Lidia Boghean, Connor Branick, Kunle Odunsi, Ronny Drapkin, Lee Zou, Adam R. Karpf

Summary: FOXM1 and RHNO1 are co-amplified and co-expressed in high-grade serous carcinoma, and their bidirectional promoter may serve as a potential therapeutic target for ovarian and other cancers. Their oncogenic properties in HGSC cells highlight the significance of targeting the FOXM1/RHNO1 gene pair in cancer therapy.

ELIFE (2021)

Review Oncology

Treatment of cervical cancer: overcoming challenges in access to brachytherapy

Katie Lichter, Chidinma Anakwenze Akinfenwa, Emily MacDuffie, Rohini Bhatia, Christina Small, Jennifer Croke, William Small, Junzo Chino, Daniel Petereit, Surbhi Grover

Summary: Brachytherapy is an essential component of cervical cancer treatment, but its global utilization is low and there are disparities in access. This review explores the current utilization practices and efforts to address barriers to implementation, emphasizing the need to expand access to brachytherapy for women in need worldwide.

EXPERT REVIEW OF ANTICANCER THERAPY (2022)

Review Oncology

Gynecologic radiation therapy in low and middle income countries during the COVID-19 pandemic

Rohini K. Bhatia, Katie E. Lichter, Lavanya Gurram, Emily MacDuffie, Dorothy Lombe, Gustavo R. Sarria, Surbhi Grover

Summary: The COVID-19 pandemic has had a global impact on the use of radiation therapy for gynecologic cancers. This review explores the guidelines for using radiation therapy during the pandemic and discusses how different countries have adapted to these guidelines based on their individual resources, government restrictions, and societal norms. The article also emphasizes the importance of utilizing various fractionation schemes and technologies when resources are limited.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2022)

Review Oncology

The state of gynecologic radiation therapy in low- and middle-income countries

Rohini Bhatia, Katie E. Lichter, Lavanya Gurram, Emily MacDuffie, Dorothy Lombe, Gustavo R. Sarria, Surbhi Grover

Summary: Gynecologic malignancies pose a disproportionate burden in low- and middle-income countries, and radiation therapy plays a crucial role in their treatment. Understanding the disease epidemiology and availability of radiation therapy infrastructure is vital to improve patient care. Different geographic regions face unique challenges, including limited access to radiation equipment, geographic barriers, and lack of specialized training. Successful examples of telemedicine and cross-cultural partnerships have helped enhance access to adequate and appropriate treatment for gynecologic malignancies.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2022)

Article Oncology

Loss of E-cadherin Induces IGF1R Activation and Reveals a Targetable Pathway in Invasive Lobular Breast Carcinoma

Ashuvinee Elangovan, Jagmohan Hooda, Laura Savariau, Susrutha Puthanmadhomnarayanan, Megan E. Yates, Jian Chen, Daniel D. Brown, Priscilla F. McAuliffe, Steffi Oesterreich, Jennifer M. Atkinson, Adrian V. Lee

Summary: No special-type breast cancer (NST) and invasive lobular carcinoma (ILC) are two major subtypes of breast cancer with significant differences in clinicopathological and molecular characteristics. Loss of E-cadherin in ILC leads to increased sensitivity to IGF1 signaling and enhanced downstream signaling. These findings suggest the importance of further exploring these targets in ILC treatment and utilizing CDH1 loss as a biomarker for patient stratification.

MOLECULAR CANCER RESEARCH (2022)

Review Oncology

Use of Glucocorticoids in Patients With Cancer: Potential Benefits, Harms, and Practical Considerations for Clinical Practice

Kristine N. Kim, Michael LaRiviere, Emily Macduffie, Caitlin A. White, Mary M. Jordan-Luft, Eleanor Anderson, Matthew Ziegler, Jacob A. Radcliff, Joshua Jones

Summary: The purpose of this review is to update our knowledge on the usage of glucocorticoids in adult cancer patients. Glucocorticoids can be highly effective in improving outcomes and quality of life in patients with cancer, mainly used for managing disease manifestations, symptoms, and complications of cancer treatment. The lowest effective dose should be used and treatment duration should be minimized. Side effects can be minimized by careful monitoring, continued assessment of benefits versus harms, and preventative measures.

PRACTICAL RADIATION ONCOLOGY (2023)

Review Oncology

Cell Competition in Carcinogenesis

Esha Madan, Antonio M. Palma, Vignesh Vudatha, Jose G. Trevino, Kedar Nath Natarajan, Robert A. Winn, Kyoung Jae Won, Trevor A. Graham, Ronny Drapkin, Stuart A. C. McDonald, Paul B. Fisher, Rajan Gogna

Summary: The majority of human cancers evolve through the accumulation of somatic mutations and clonal selection. The mechanisms governing clonal dynamics and selection during the early stages of tissue transformation are still unclear. Cell competition, known as "survival of the fittest" at the cellular level, can eliminate less fit cells or lead to the uncontrolled expansion of super-fit cancer cells. Recent research has highlighted the role of interclonal competition and cancer microenvironment competition in tumor progression.

CANCER RESEARCH (2022)

Review Biotechnology & Applied Microbiology

Drugging p53 in cancer: one protein, many targets

Ori Hassin, Moshe Oren

Summary: Mutations in the TP53 gene are common in cancer, but restoring p53 functionality has been considered impossible for a long time. However, recent years have seen promising developments in p53-based therapy, including improved strategies and novel approaches. Small molecules that protect or restore p53 function are gaining interest, along with tailored drugs for specific p53 mutants. Additionally, gene therapy and immunotherapy are being reconsidered. However, significant challenges remain.

NATURE REVIEWS DRUG DISCOVERY (2023)

Article Biology

L1CAM is required for early dissemination of fallopian tube carcinoma precursors to the ovary

Kai Doberstein, Rebecca Spivak, Hunter D. Reavis, Jagmohan Hooda, Yi Feng, Paul T. Kroeger, Sarah Stuckelberger, Gordon B. Mills, Kyle M. Devins, Lauren E. Schwartz, Marcin P. Iwanicki, Mina Fogel, Peter Altevogt, Ronny Drapkin

Summary: This research provides evidence that L1 cell adhesion molecule (L1CAM) plays a role in the dissemination of transformed fallopian tube secretory cells (FTSECs) to the ovary in the early stages of high-grade serous carcinoma (HGSC) development. L1CAM upregulates integrins and fibronectin in malignant cells and activates the AKT and ERK pathways, increasing cell survival under non-adherent conditions and facilitating ovarian colonization.

COMMUNICATIONS BIOLOGY (2022)

Article Oncology

FOXA1 Reprogramming Dictates Retinoid X Receptor Response in ESR1-Mutant Breast Cancer

Yang Wu, Zheqi Li, Abdalla M. Wedn, Allison N. Casey, Daniel Brown, Shalini Rao, Soleilmane Omarjee, Jagmohan Hooda, Jason S. Carroll, Jason Gertz, Jennifer M. Atkinson, Adrian Lee, Steffi Oesterreich

Summary: Estrogen receptor alpha (ER/ESR1) mutations are common in endocrine resistant ER-positive breast cancer. Forkhead box A1 (FOXA1) plays a role in ER-chromatin interactions and endocrine response, but its role in ESR1-mutant breast cancer is unclear. This study shows that FOXA1 redistribution is associated with transcriptomic alterations caused by ESR1 mutations and suggests targeting the retinoid X receptor (RXR) pathway as a therapeutic strategy for breast tumors with ESR1 mutation.

MOLECULAR CANCER RESEARCH (2023)

Article Cell Biology

Deciphering the involvement of the Hippo pathway co-regulators, YAP/TAZ in invadopodia formation and matrix degradation

Jubina Balan Venghateri, Bareket Dassa, David Morgenstern, Michal Shreberk-Shaked, Moshe Oren, Benjamin Geiger

Summary: This study investigates the involvement of YAP and TAZ, key regulators of the Hippo pathway, in invadopodia formation and matrix degradation. Knockdown or inhibition of YAP and TAZ enhances matrix degradation and invadopodia formation in multiple cancer cell lines, while overexpression suppresses these processes. Proteomic and transcriptomic analysis reveals changes in levels of key invadopodia-associated proteins. These findings suggest that YAP and TAZ act as negative regulators of invadopodia formation by reducing levels of essential invadopodia components. Understanding the molecular mechanisms of invadopodia formation in cancer invasion may lead to the identification of novel therapeutic targets.

CELL DEATH & DISEASE (2023)

Article Oncology

KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in Ovarian Cancer

Heng Liu, Jianhuang Lin, Wei Zhou, Renyta Moses, Zhongping Dai, Andrew V. Kossenkov, Ronny Drapkin, Benjamin G. Bitler, Sergey Karakashev, Rugang Zhang

Summary: This study demonstrates that the extent of effector CD8+ T cell infiltration into tumors is influenced by a histone H3 demethylase (KDM5A) in epithelial ovarian cancer. KDM5A inhibits immune cell infiltration and antitumor immune responses by silencing genes involved in antigen processing and presentation. Inhibition of KDM5A restores gene expression in the antigen-presentation pathway and promotes antitumor immune responses mediated by CD8+ T cells.

CANCER IMMUNOLOGY RESEARCH (2022)

Review Medicine, Research & Experimental

Tumor innervation: peripheral nerves take control of the tumor microenvironment

Stefan M. Gysler, Ronny Drapkin

Summary: Recent cancer research has shifted focus from abnormal cell division to the complex interactions between cancer and noncancer cells in the tumor microenvironment. The recruitment of peripheral nerves to the TME by tumors has been linked to enhanced tumor growth and aggressive tumor behavior, suggesting a potential role for the peripheral nervous system in cancer development. Emerging evidence also suggests that exosomes may mediate neural regulation of the TME through cell-cell communication.

JOURNAL OF CLINICAL INVESTIGATION (2021)

No Data Available